{"id":"W4413112190","doi":"10.1136/jitc-2025-012478","title":"Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"EMD Serono; LEO Pharma; PharmaMar; Servier; Eisai; Fred Hutchinson Cancer Research Center; Regeneron Pharmaceuticals; Springworks Therapeutics; Advanced Accelerator Applications; Incyte; Les Laboratories Pierre Fabre; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Merkel cell carcinoma; Tolerability; Internal medicine; Clinical endpoint; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy; Surgery; Carcinoma; Adverse effect; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001635831,0.0001849289,0.0006028999,0.000286734,0.00009198102,0.000007137741,0.0001315569,0.00004411622,0.00010841],"category_scores_gemma":[0.0000235595,0.0001117032,0.000142976,0.0003258778,0.00006326695,0.00009139679,0.00001583459,0.0002270046,1.604586e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001465861,"about_ca_system_score_gemma":0.0006466873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001377223,"about_ca_topic_score_gemma":0.00007010577,"domain_scores_codex":[0.9984835,0.00005078686,0.0007165158,0.0001682573,0.000350484,0.0002304863],"domain_scores_gemma":[0.9988099,0.00004905002,0.0004787148,0.0002200644,0.0003672803,0.00007494361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2981631,0.0552153,0.07746309,0.0008260596,0.002275923,0.00004026473,0.003564588,0.0004011577,0.01327394,0.00001003542,0.00105887,0.5477077],"study_design_scores_gemma":[0.4944687,0.1617801,0.309174,0.004468823,0.002343328,0.000009143716,0.003175523,0.0003138577,0.01706256,0.0001489665,0.006480389,0.0005745369],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807196,0.01719739,0.00008252212,0.0001115986,0.0003709939,0.001365458,0.00006942853,0.000005339135,0.00007765778],"genre_scores_gemma":[0.9974457,0.001136469,0.0003903451,0.0001060719,0.0000180248,0.00007305742,0.000006477876,0.00002661493,0.0007972204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5471331,"threshold_uncertainty_score":0.4555123,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01389871285557377,"score_gpt":0.3462098475511426,"score_spread":0.3323111346955689,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}